COO Stock Analysis — CooperCompanies
Sector: Healthcare
AI Verdict
CooperCompanies trades at 14.8x next year's earnings while analysts expect nearly 300% EPS growth—cheap for the growth on offer if its specialty lens moat holds and the rebound proves real.
Competitive Moat
CooperCompanies dominates the specialty contact lens market, where its proprietary lens materials and fit technologies create switching costs for eye care professionals and patients. Its scale and deep relationships with optometrists help defend its share against generic and new entrants.
Summary
A dramatic drop in forward P/E to 14.8x with analyst consensus calling for +296.5% EPS growth makes this a rare reset in healthcare.
Where It Stands
The stock is deeply oversold with an RSI of 22.9, up just 2.20% over the past year, and trades at 14.8x forward earnings versus a sector median of 22x.
Key Metrics
- RSI: 22.9 — Oversold
- Trailing P/E: 58.8x
- Forward P/E: 14.8x
- PEG Ratio: 0.20
- Earnings Growth: +3.0%
- Revenue Growth: +0.1%
- Market Cap: $13.6B
- Dividend Yield: 0.00%
- 1-Year Return: 2.20%
- 52-Week High: $89.83
- 52-Week Low: $58.89
Analyst Consensus
13 Buy · 10 Hold · 0 Sell (23 analysts)
Bull Case
Analysts expect a staggering 296.5% jump in EPS next year, so the current 14.8x forward P/E is cheap for that level of growth if the rebound materializes.
Bear Case
If the forward P/E reverts even partway to its trailing 58.8x, or if the RSI mean-reverts, a failed earnings rebound could mean a sharp drop from current levels.
Catalyst to Watch
Watch for the next quarterly earnings report to confirm whether the expected earnings surge is on track.